Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.385 AUD | -12.50% |
|
+4.05% | +120.00% |
Jun. 26 | Cleo Diagnostics Secures US FDA Feedback for Ovarian Cancer Test | MT |
Jun. 23 | 7,500,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 23-JUN-2024. | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
+120.00% | 38.13M | |
-6.56% | 12.02B | |
-19.37% | 6.81B | |
+5.28% | 5.74B | |
+27.24% | 5.47B | |
-21.19% | 3.59B | |
+6.64% | 2.56B | |
+30.09% | 2.25B | |
-66.53% | 2.24B | |
-12.84% | 2.21B |
- Stock Market
- Equities
- COV Stock
- News Cleo Diagnostics Ltd
- Cleo Diagnostics Taps Lindus Health to Manage US Ovarian Cancer Clinical Trials